Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409691 | 0.87 | SMN1; SMN2 (0.54) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL18409743 | 0.87 | CDK4 (0.42) | LMNAMAPTCDK4CCND1GAA | |
| SCHEMBL18409741 | 0.86 | MAPT (0.50) | LMNAMAPTCDK4CCND1SMN1; SMN2 | |
| SCHEMBL18409641 | 0.84 | CDK4 (0.47) | CDK4CCND1KMT2AMEN1RXRA | |
| SCHEMBL18409571 | 0.83 | GPR84 (0.50) | MAPTCDK4CCND1KMT2AALDH1A1 | |
| SCHEMBL18409306 | 0.82 | CDK4 (0.51) | LMNAMAPTCDK4CCND1ICMT | |
| SCHEMBL18409637 | 0.81 | CDK4 (0.46) | CDK4CCND1KMT2AMEN1RXRA | |
| SCHEMBL20414447 | 0.81 | NR4A2 (0.53) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL18409307 | 0.80 | LMNA (0.53) | LMNAMAPTCDK4CCND1GAA | |
| SCHEMBL18409747 | 0.79 | CDK4 (0.49) | LMNAMAPTCDK4CCND1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY | 2020-11-24 | — | — | US | disclosed |
| US-20200339554-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-10-29 | — | — | US | disclosed |
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-07-26 | — | — | US | disclosed |
| WO-2017011920-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | VHL, TP53, CD44 | LMNA 1482/4885MAPT 1911/4885CDK4 357/4885 |
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | OXA1L, PDCD1, MCL1 | LMNA 4635/4885MAPT 4624/4885CDK4 76/4885 |
| US-20200339554-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | KRAS, NRAS, VHL | LMNA 2809/4885MAPT 3997/4885CDK4 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.